Pulmatrix Total Operating Expenses vs Selling And Marketing Expenses Analysis
| PULM Stock | USD 6.29 0.25 4.14% |
Pulmatrix financial indicator trend analysis is much more than just breaking down Pulmatrix prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pulmatrix is a good investment. Please check the relationship between Pulmatrix Total Operating Expenses and its Selling And Marketing Expenses accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.
Total Operating Expenses vs Selling And Marketing Expenses
Total Operating Expenses vs Selling And Marketing Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pulmatrix Total Operating Expenses account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have pay attention.
The correlation between Pulmatrix's Total Operating Expenses and Selling And Marketing Expenses is -0.79. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of Pulmatrix, assuming nothing else is changed. The correlation between historical values of Pulmatrix's Total Operating Expenses and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Pulmatrix are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Total Operating Expenses i.e., Pulmatrix's Total Operating Expenses and Selling And Marketing Expenses go up and down completely randomly.
Correlation Coefficient | -0.79 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Selling And Marketing Expenses
Most indicators from Pulmatrix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pulmatrix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.At this time, Pulmatrix's Selling General Administrative is very stable compared to the past year. As of the 27th of November 2024, Enterprise Value Over EBITDA is likely to grow to 0.29, while Sales General And Administrative To Revenue is likely to drop 0.85.
Pulmatrix fundamental ratios Correlations
Click cells to compare fundamentals
Pulmatrix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pulmatrix fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Stockholder Equity | 11.0M | 23.1M | 47.4M | 31.1M | 18.0M | 18.9M | |
| Retained Earnings | (215.2M) | (234.5M) | (254.6M) | (273.5M) | (287.6M) | (273.2M) | |
| Common Stock Shares Outstanding | 836.7K | 1.4M | 2.7M | 3.4M | 3.7M | 3.8M | |
| Other Stockholder Equity | 226.2M | 257.6M | 301.0M | 304.6M | 305.6M | 175.4M | |
| Total Assets | 36.1M | 38.2M | 58.8M | 41.0M | 34.0M | 30.4M | |
| Other Current Liab | 2.5M | 893K | (198K) | 781K | 518K | 543.9K | |
| Total Current Liabilities | 17.2M | 8.3M | 4.4M | 5.0M | 3.9M | 5.3M | |
| Property Plant And Equipment Net | 900K | 1.9M | 2.4M | 945K | 11.5M | 12.0M | |
| Current Deferred Revenue | 13.4M | 4.2M | 939K | 1.3M | 618K | 648.9K | |
| Net Debt | (22.8M) | (29.9M) | (51.6M) | (34.8M) | (10.4M) | (10.9M) | |
| Accounts Payable | 600K | 851K | 839K | 1.2M | 1.9M | 2.0M | |
| Cash | 23.4M | 31.7M | 53.8M | 35.6M | 19.2M | 20.5M | |
| Non Current Assets Total | 4.7M | 5.6M | 4.0M | 2.8M | 13.1M | 8.2M | |
| Cash And Short Term Investments | 23.4M | 31.7M | 53.8M | 35.6M | 19.2M | 20.5M | |
| Net Receivables | 7.2M | 84K | 67K | 1.3M | 928K | 1.0M | |
| Liabilities And Stockholders Equity | 36.1M | 38.2M | 58.8M | 41.0M | 34.0M | 30.4M | |
| Non Current Liabilities Total | 7.9M | 6.8M | 6.9M | 4.8M | 12.1M | 12.7M | |
| Other Current Assets | 221K | 723K | 871K | 1.1M | 1.1M | 566.2K | |
| Total Liab | 25.1M | 15.0M | 11.4M | 9.8M | 16.0M | 9.9M | |
| Property Plant And Equipment Gross | 900K | 361.0 | 2.4M | 945K | 13.2M | 13.9M | |
| Total Current Assets | 31.4M | 32.5M | 54.8M | 38.1M | 20.8M | 22.2M | |
| Short Term Debt | 675K | 2.3M | 2.9M | 1.7M | 858K | 815.1K | |
| Net Tangible Assets | 7.4M | 19.6M | 46.4M | 31.1M | 35.8M | 37.6M | |
| Retained Earnings Total Equity | (174.0M) | (194.6M) | (215.2M) | (234.5M) | (211.0M) | (221.6M) | |
| Capital Surpluse | 184.1M | 206.4M | 226.2M | 257.6M | 296.2M | 191.7M | |
| Property Plant Equipment | 270K | 1.9M | 2.4M | 945K | 1.1M | 991.8K | |
| Net Invested Capital | 11.0M | 23.1M | 46.4M | 31.1M | 18.0M | 24.3M | |
| Net Working Capital | 14.2M | 24.3M | 50.3M | 33.1M | 16.9M | 21.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 3.119 | Quarterly Revenue Growth (0.16) | Return On Assets (0.30) | Return On Equity (0.59) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.